Compare Ascendis Pharma A/S (ASND) vs Anheuser-Busch Inbev SA (BUD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Anheuser-Busch Inbev SA — how do they compare? Ascendis Pharma A/S trades at $263 (market cap $17.74B), while Anheuser-Busch Inbev SA trades at $79.14 (market cap $153.32B). The key difference: Anheuser-Busch Inbev SA is far larger — about 8.6× Ascendis Pharma A/S's market cap, and Anheuser-Busch Inbev SA pays a 1.69% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BUD | |
|---|---|---|
Market Cap | $17.74B | $153.32B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $85.09 |
52-Week Low | $163.32 | $57.10 |
Enterprise Value | $18.11B | $214.50B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BUD trades at $79.61, up 0.34% on the day, with a bearish technical signal despite recent earnings beats. The company shows stable revenue near $59B and improving net margins, now at 11.9%. Analyst consensus is bullish with a $90.08 price target, supported by dividend payments and strategic investments in premiumization and digital expansion.
Outlook remains positive due to strong fundamentals and analyst support, but risks include industry volume declines and competitive pressures. The stock offers value through dividends and potential upside to target, though technical weakness suggests near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →
